A call to action for deciphering genetic variants in human pluripotent stem cells for cell therapy.
| Title: | A call to action for deciphering genetic variants in human pluripotent stem cells for cell therapy. |
|---|---|
| Authors: | Benvenisty N; The Azrieli Center for Stem Cells and Genetic Research, Department of Genetics, Institute of Life Sciences, The Hebrew University, Jerusalem 91904, Israel.; Draper JS; Stem Cell Network, Ottawa, ON K1R 1A4, Canada.; Gokhale PJ; School of Biosciences, The University of Sheffield, Western Bank, Sheffield S10 2TN, UK.; Healy L; Human Embryo and Stem Cell Unit, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.; Hewitt Z; School of Biosciences, The University of Sheffield, Western Bank, Sheffield S10 2TN, UK.; Hursh D; Hursh Cell Therapy Consulting, LLC, Ashton, MD, USA.; Hodgson A; School of Biosciences, The University of Sheffield, Western Bank, Sheffield S10 2TN, UK.; Ludwig TE; WiCell Research Institute, Madison, WI, USA; University of Wisconsin - Madison, Madison, WI, USA.; Mah N; Fraunhofer Institute for Biomedical Engineering (IBMT), Joseph-von-Fraunhofer-Weg 1, 66280 Sulzbach, Germany.; McClelland SE; Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6AU, UK.; Mennecozzi M; European Commission, Joint Research Centre (JRC), Ispra, Italy.; Merkle FT; Department of Pharmacology, the Institute of Metabolic Science, and the Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, UK.; Mountford JC; Scottish National Blood Transfusion Service, Jack Copland Centre, Edinburgh EH14 4BE, UK.; Pera M; The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA.; Prigione A; Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.; Rodriguez TA; National Heart and Lung Institute, Imperial College London, Du Cane Road, London W12 0NN, UK.; Rossi A; Genome Engineering and Model Development Laboratory, IUF-Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany.; Rouhani FJ; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.; Saeb-Parsy K; Department of Surgery, University of Cambridge, and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Selfa Aspiroz L; European Commission, Joint Research Centre (JRC), Ispra, Italy.; Shakiba N; School of Biomedical Engineering, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; Premium Research Institute for Human Metaverse Medicine (PRIMe), Osaka University, Osaka, Japan.; Spits C; Vrije Universiteit Brussel (VUB), Brussels Health Campus/Faculty of Medicine and Pharmacy, Research Group Genetics, Reproduction and Development, Laarbeeklaan 103, 1090 Brussels, Belgium.; Tonge PD; bit.bio, The Dorothy Hodgkin Building, Babraham Research Campus, Cambridge CB22 3FH, UK.; Barbaric I; School of Biosciences, The University of Sheffield, Western Bank, Sheffield S10 2TN, UK; Neuroscience Institute, The University of Sheffield, Western Bank, Sheffield S10 2TN, UK; INSIGNEO Institute, The University of Sheffield, Western Bank, Sheffield S10 2TN, UK. Electronic address: i.barbaric@sheffield.ac.uk. |
| Source: | Cell stem cell [Cell Stem Cell] 2025 Apr 03; Vol. 32 (4), pp. 508-512. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101311472 Publication Model: Print Cited Medium: Internet ISSN: 1875-9777 (Electronic) Linking ISSN: 18759777 NLM ISO Abbreviation: Cell Stem Cell Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Cambridge, MA : Cell Press |
| MeSH Terms: | Pluripotent Stem Cells*/metabolism ; Pluripotent Stem Cells*/cytology ; Cell- and Tissue-Based Therapy*/methods ; Genetic Variation*; Humans |
| Abstract: | Human pluripotent stem cell (hPSC)-based therapies offer promise but pose potential risks due to culture-acquired genetic variants, some of which have been linked with cancer. An international workshop addressed these concerns, highlighting the need for improved strategies to stratify variants and chart a path toward definitive guidelines in hPSC-based therapy.; (Copyright © 2025 Elsevier Inc. All rights reserved.) |
| Competing Interests: | Declaration of interests Z.H. is a co-founder and majority shareholder of Regenerative Cell Therapy Consulting, Ltd. D.H. is the founder and principal of Hursh Cell Therapy Consulting. |
| Entry Date(s): | Date Created: 20250404 Date Completed: 20250515 Latest Revision: 20250515 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.stem.2025.03.003 |
| PMID: | 40185071 |
| Database: | MEDLINE |
Journal Article